StockData

Scienture vs Exicure

SCNX and XCUR side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How SCNX and XCUR compare

Scienture is the larger company, worth 18 times as much as Exicure ($123M against $7.0M).

Exicure scores higher on the StockData Score (4 against 3 for Scienture), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricSCNXXCUR
Size and price
Market cap$123M$7.0M
Share price$2.99$1.07
Change, 1 year−82.2%−70.7%
Change, 5 years−99.8%−98.6%
Beta (5Y)1.07−0.97
Employees88
StockData Score
Total score34 (better)
Valuation score1 (better)0
Growth score00
Performance score1 (better)0
Health score14 (better)
Dividend score00
Valuation
P/B1.9× (better)7.2×
Growth
Revenue growth, 5Y average−52.1%–
Profitability
Return on equity−53.5% (better)−168%
Return on invested capital−47.3% (better)−4377%
Financial health
Debt / equity–0.00
Interest coverage−13.1×–
Current ratio3.04 (better)0.56
Altman Z-score0.31 (better)−27.36
Piotroski F-score4 (better)2
Dividends and buybacks
Buyback yield–0.00%
Shareholder yield0.00%0.00%
Ownership
Held by institutions–2.1%
Held by insiders16.6%92.6%
Insider net buying, 12 months–−$11.6M
Short interest, % of float0.34%10.8%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.